The purpose of the Animal Models Core facility is to support and centralize certain aspects of the work ineach project proposed. It is our belief that prostate cancer biology is best studied in animal model systemsthat allow experimental monitoring of progression events such as metastasis and androgen-independentprogression. This facility brings together expertise in mouse genetics and human tumor xenografs that willallow basic molecular biological questions to be addressed in state-of-the art model systems with directrelevance to the clinical situation. It also offers an opportunity for translational research questions to beaddressed immediately in relevant pre-clinical models. The Core consists of six distinct components whichwill allow biologically based hypotheses to be tested in Suitable animal models or human prostate cancerxenografts.
The Specific Aims of this Core are as follows:1. To provide SCID mice to the five research projects2. To propagate four human prostate cancer xenografts: LAPC4, LAPC9, CWR22, and LUCAP on SCIDmice for Investigators in the SPORE.3. To maintain model mice, such as Pten and Cox-2 conditional knock-out, AKT and Myc transgenic miceas well as reporter lines needed for each project.4. To provide technical assistance for in vivo experiments, such as harvest xenografts, measure PSA level,and inject pro-drugs for pre-clinical trials.5. To provide expertise/consultation on animal experimentation and surgical techniques required for theproposed studies.6. To provide expertise/consultation for the generation of new models.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA092131-06
Application #
7315095
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (M1))
Project Start
2007-07-01
Project End
2012-06-30
Budget Start
2007-07-01
Budget End
2008-06-30
Support Year
6
Fiscal Year
2007
Total Cost
$85,563
Indirect Cost
Name
University of California Los Angeles
Department
Type
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Tan, Nelly; Shen, Luyao; Khoshnoodi, Pooria et al. (2018) Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology. J Urol 199:1218-1223
Donin, Nicholas M; Reiter, Robert E (2018) Why Targeting PSMA Is a Game Changer in the Management of Prostate Cancer. J Nucl Med 59:177-182
Nagarajan, Mahesh B; Raman, Steven S; Lo, Pechin et al. (2018) Building a high-resolution T2-weighted MR-based probabilistic model of tumor occurrence in the prostate. Abdom Radiol (NY) 43:2487-2496
Calais, Jeremie; Fendler, Wolfgang P; Eiber, Matthias et al. (2018) Impact of 68Ga-PSMA-11 PET/CT on the Management of Prostate Cancer Patients with Biochemical Recurrence. J Nucl Med 59:434-441
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Neutrophil, lymphocyte and platelet counts, and risk of prostate cancer outcomes in white and black men: results from the SEARCH database. Cancer Causes Control 29:581-588
Vidal, Adriana C; Howard, Lauren E; de Hoedt, Amanda et al. (2018) Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int 122:76-82
Jelinek, David; Flores, Aimee; Uebelhoer, Melanie et al. (2018) Mapping Metabolism: Monitoring Lactate Dehydrogenase Activity Directly in Tissue. J Vis Exp :
Lee, John K; Bangayan, Nathanael J; Chai, Timothy et al. (2018) Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A 115:E4473-E4482
Mitra, Mithun; Lee, Ha Neul; Coller, Hilary A (2018) Determining Genome-wide Transcript Decay Rates in Proliferating and Quiescent Human Fibroblasts. J Vis Exp :
Zou, Yongkang; Qi, Zhi; Guo, Weilong et al. (2018) Cotargeting the Cell-Intrinsic and Microenvironment Pathways of Prostate Cancer by PI3K?/?/? Inhibitor BAY1082439. Mol Cancer Ther 17:2091-2099

Showing the most recent 10 out of 339 publications